Company: SNY
Filing Date: 2025-06-17
Form Type: SC TO-T
Source: 0001193125-25-141704
Chunk: 1

Company: Sanofi
Filing Date: 2025-06-17
Form: SC TO-T
Chunk 1
---
 | Rule 13e-4(i) (Cross-Border Issuer Tender Offer) |

| ☐ | Rule 14d-1(d) (Cross-Border Third-Party Tender Offer) |

This Tender Offer Statement on Schedule TO (together with any amendments and supplements hereto, this
“”) is filed by (i) Rothko Merger Sub, Inc., a Delaware corporation (“”) and an indirect wholly owned subsidiary of SANOFI, a French sociétéanonyme(“”), (ii) Parent and (iii) Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent and direct parent of Purchaser (“”). This Schedule TO relates to the offer by
Purchaser to purchase all of the outstanding shares of common stock, par value, $0.001 per share (the “”), of Blueprint Medicines Corporation, a Delaware corporation (the “”), for $129.00 per Share in
cash, without interest (the “”) and subject to any withholding of taxes required by applicable legal requirements, plus one (1) non-transferable contractual contingent
value right (each, a “”) per Share, representing the right to receive contingent payments of up to an aggregate amount of $6.00 per Share in cash, without interest, upon the achievement of one or both of the milestones on or
prior to the expiration of the applicable milestone period set forth in the Contingent Value Rights Agreement (the “”) to be entered into with a rights agent (the “”) mutually agreeable to
Aventis and the Company (the CVR, together with the Cash Offer Price, or any other amount paid pursuant to the Offer to the extent permitted under the Merger Agreement (as defined below), the “”). Such offer is
being made upon the terms and subject to the conditions set forth in the Offer to Purchase, dated June 17, 2025 (together with any amendments or supplements thereto, the “”) and in the accompanying Letter of
Transmittal, which are annexed to and filed with this Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively.

All information contained in
the Offer to Purchase (including Schedule I to the Offer to Purchase) and the accompanying Letter of Transmittal is hereby expressly incorporated herein by reference in response to Items 1 through 9 and Item 11 of this Schedule TO.

The Agreement and Plan of Merger, dated as of June 2, 202